Intellia Therapeutics Shows Significant Progress, Stock Up 58%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Yahoo Finance
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after the FDA placed two phase 3 studies on hold, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Progress: On April 27, Intellia announced phase 3 trial results for lonvo-z, showing an 87% reduction in attacks and 62% of patients completely free of attacks after a single infusion, indicating the therapy's potential to become the standard of care for HAE.
- Market Opportunity Assessment: Although there are only about 7,000 HAE patients, lonvo-z could represent a market opportunity of $7 billion, with an estimated lifetime sales of $3.5 billion assuming a 50% penetration rate, highlighting its commercial value.
- Future Development Prospects: Intellia is also developing nex-z for treating ATTR, with a global patient population of 250,000 to 500,000; if clinical trials succeed, it could significantly enhance the company's outlook and drive further stock price increases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 15.200
Low
4.00
Averages
16.50
High
54.00
Current: 15.200
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after overcoming a temporary hold by the FDA on two phase 3 studies, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Effectiveness: In a recent phase 3 clinical trial, patients treated with lonvo-z experienced an 87% reduction in attacks, with 62% completely attack-free, indicating significant efficacy in treating hereditary angioedema and potential to become the standard of care.
- Substantial Market Opportunity: Although the hereditary angioedema patient population is only about 7,000 in the U.S., lonvo-z could represent a market size of $7 billion, with estimated lifetime sales of $3.5 billion at a 50% penetration rate, highlighting its commercial appeal.
- Future Growth Potential: Intellia is also developing nex-z for transthyretin amyloidosis, with a patient population of 250,000 to 500,000 globally; successful clinical trials could further enhance the company's stock price and market position.
See More
Intellia Therapeutics' Drug Phase 3 Trial Success
- Clinical Trial Success: Intellia Therapeutics' lonvo-z achieved positive results in a phase 3 trial for hereditary angioedema, with an 87% reduction in attacks after a single infusion, demonstrating the drug's efficacy and market appeal.
- Market Potential Assessment: Although the patient population for lonvo-z is only about 7,000, with a treatment cost of $1 million, its total addressable market in the U.S. could reach $7 billion, suggesting a potential lifetime sales of $3.5 billion, reflecting significant commercial value.
- Regulatory Progress: Intellia has begun submitting its application to the FDA for lonvo-z approval, aiming for a launch in the first half of 2027, which could establish it as the standard of care for hereditary angioedema and enhance the company's market position.
- Future Development Risks: Despite lonvo-z's promising outlook, Intellia faces clinical and regulatory risks, particularly with its other candidate nex-z, which has been put on clinical hold by the FDA, necessitating cautious evaluation of potential volatility by investors.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after the FDA placed two phase 3 studies on hold, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Progress: On April 27, Intellia announced phase 3 trial results for lonvo-z, showing an 87% reduction in attacks and 62% of patients completely free of attacks after a single infusion, indicating the therapy's potential to become the standard of care for HAE.
- Market Opportunity Assessment: Although there are only about 7,000 HAE patients, lonvo-z could represent a market opportunity of $7 billion, with an estimated lifetime sales of $3.5 billion assuming a 50% penetration rate, highlighting its commercial value.
- Future Development Prospects: Intellia is also developing nex-z for treating ATTR, with a global patient population of 250,000 to 500,000; if clinical trials succeed, it could significantly enhance the company's outlook and drive further stock price increases.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
Intellia's Treatment Candidate Shows Promising Results
- Stock Surge: Intellia Therapeutics Inc. experienced a 23.20% increase in share price, closing at $14.92, reflecting investor optimism regarding the promising results of its treatment candidate Lonvo-Z, indicating strong market confidence in its future potential.
- Significant Efficacy: Lonvo-Z achieved an 87% reduction in mean monthly attacks from weeks 5 to 28 compared to the placebo group, meeting its primary endpoint and demonstrating substantial effectiveness in treating hereditary angioedema (HAE), which could significantly improve patients' quality of life.
- Positive Patient Outcomes: Among enrolled patients, 62% in the Lonvo-Z arm were completely attack-free and therapy-free during the six-month efficacy evaluation period, compared to only 11% in the placebo group, underscoring the treatment's efficacy and safety profile.
- Future Development Plans: Intellia is on track to launch Lonvo-Z in the first half of 2027 and submitted a rolling biologics license application to the FDA in April, showcasing the company's commitment to advancing innovative therapies.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after overcoming a temporary hold by the FDA on two phase 3 studies, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Effectiveness: In a recent phase 3 clinical trial, patients treated with lonvo-z experienced an 87% reduction in attacks, with 62% completely attack-free, indicating significant efficacy in treating hereditary angioedema and potential to become the standard of care.
- Substantial Market Opportunity: Although the hereditary angioedema patient population is only about 7,000 in the U.S., lonvo-z could represent a market size of $7 billion, with estimated lifetime sales of $3.5 billion at a 50% penetration rate, highlighting its commercial appeal.
- Future Growth Potential: Intellia is also developing nex-z for transthyretin amyloidosis, with a patient population of 250,000 to 500,000 globally; successful clinical trials could further enhance the company's stock price and market position.
See More
Intellia Therapeutics' Drug Phase 3 Trial Success
- Clinical Trial Success: Intellia Therapeutics' lonvo-z achieved positive results in a phase 3 trial for hereditary angioedema, with an 87% reduction in attacks after a single infusion, demonstrating the drug's efficacy and market appeal.
- Market Potential Assessment: Although the patient population for lonvo-z is only about 7,000, with a treatment cost of $1 million, its total addressable market in the U.S. could reach $7 billion, suggesting a potential lifetime sales of $3.5 billion, reflecting significant commercial value.
- Regulatory Progress: Intellia has begun submitting its application to the FDA for lonvo-z approval, aiming for a launch in the first half of 2027, which could establish it as the standard of care for hereditary angioedema and enhance the company's market position.
- Future Development Risks: Despite lonvo-z's promising outlook, Intellia faces clinical and regulatory risks, particularly with its other candidate nex-z, which has been put on clinical hold by the FDA, necessitating cautious evaluation of potential volatility by investors.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after the FDA placed two phase 3 studies on hold, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Progress: On April 27, Intellia announced phase 3 trial results for lonvo-z, showing an 87% reduction in attacks and 62% of patients completely free of attacks after a single infusion, indicating the therapy's potential to become the standard of care for HAE.
- Market Opportunity Assessment: Although there are only about 7,000 HAE patients, lonvo-z could represent a market opportunity of $7 billion, with an estimated lifetime sales of $3.5 billion assuming a 50% penetration rate, highlighting its commercial value.
- Future Development Prospects: Intellia is also developing nex-z for treating ATTR, with a global patient population of 250,000 to 500,000; if clinical trials succeed, it could significantly enhance the company's outlook and drive further stock price increases.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
Intellia's Treatment Candidate Shows Promising Results
- Stock Surge: Intellia Therapeutics Inc. experienced a 23.20% increase in share price, closing at $14.92, reflecting investor optimism regarding the promising results of its treatment candidate Lonvo-Z, indicating strong market confidence in its future potential.
- Significant Efficacy: Lonvo-Z achieved an 87% reduction in mean monthly attacks from weeks 5 to 28 compared to the placebo group, meeting its primary endpoint and demonstrating substantial effectiveness in treating hereditary angioedema (HAE), which could significantly improve patients' quality of life.
- Positive Patient Outcomes: Among enrolled patients, 62% in the Lonvo-Z arm were completely attack-free and therapy-free during the six-month efficacy evaluation period, compared to only 11% in the placebo group, underscoring the treatment's efficacy and safety profile.
- Future Development Plans: Intellia is on track to launch Lonvo-Z in the first half of 2027 and submitted a rolling biologics license application to the FDA in April, showcasing the company's commitment to advancing innovative therapies.
See More
